Citadel Advisors’s Pelthos Therapeutics PTHS Stock Holding History

Citadel Advisors’s Portfolio PTHS Stock Details PTHS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-1,871	Closed	-$24.7K	–	15408
2024 Q2	$24.7K	Buy	+1,871	New	+$31.5K	﹤0.01%	12452

Other funds holding PTHS

APP

Avantax Planning Partners Dubuque, Iowa $3.64B AUM 14.73% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Citadel Advisors's PTHS Position: Q3 2024 in Review

Citadel Advisors sold out of Pelthos Therapeutics (PTHS) in Q3 2024, closing a stake of 1,871 shares — an estimated $24.7K sold.

Citadel Advisors first reported a position in PTHS in Q2 2024 and held it in 1 quarter. The position peaked at $24.7K in Q2 2024. 5 funds tracked by Wall St. Rank hold PTHS as of Q3 2024.

Citadel Advisors reported no remaining Pelthos Therapeutics position as of Q3 2024 after selling out during the quarter.
Citadel Advisors sold 1,871 Pelthos Therapeutics shares in Q3 2024, an estimated $24.7K.
Citadel Advisors first reported a position in Pelthos Therapeutics in Q2 2024 and held it in 1 quarter.
Citadel Advisors's Pelthos Therapeutics position peaked at $24.7K in Q2 2024.
5 funds tracked by Wall St. Rank held Pelthos Therapeutics as of Q3 2024.

Based on Citadel Advisors's 13F filing for Q3 2024, filed 14 Nov 2024.